A long-term follow-up (within 18 months) has been conducted of bronchial asthma (BA) patients (a total of 29 cases with atopic, aspirin and mixed BA forms) subjected to thrombocytapheresis. The examination performed in 1-2 month intervals included a berotec test, assessment of platelet aggregation, platelet intracellular calcium metabolism, external respiration function (ERF). The treatment resulted in remission of 4-18 month duration. It was characterized by ERF normalization, high sensitivity to sympathomimetics, platelet status improvement. The best results were achieved in the groups of atopic and aspirin asthma patients. The findings allow recommendation of thrombocytapheresis as a method of choice in combined therapy of BA.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!